Competition for tissue binding sites may release retained drug and worsen skin irritation
In skin, a later application may displace retained drug from tissue binding sites, causing a damaging rise in free drug. The hypothesis is rejected if previously treated and control skin still respond differently after matching the full spatial and temporal profiles of free drug and active metabolites.
Stage of verification
- Hypothesis published2026-09-25
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Metabolism and energy
Competitive drug displacement
Release of a bound drug when other substances compete for its binding sites
Where this hypothesis actsPreviously treated skin during therapy resumption after a treatment break
Hypotheses on this target 1
Inhibition1
Activation
Function preservation
Supplementation
Feedback restoration
Direct measurement
What is proposed
Inhibition
Prevent competitive release of residual bound drug when therapy resumes
With whatNot stated in the record
HowEliminate the bound drug residue or the displacing formulation component; the procedure for doing so is not stated
Possible result
Possible stabilization of SPV_12 and resumption of therapy without increasing irritation
From the recordКомпоненты следующего нанесения конкурируют за места связывания и быстро высвобождают старый препарат.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Skin treatment could become harder to tolerate because an earlier dose remains in the skin during a break. The unexpected move is that a later application containing no new drug could release the stored dose and cause another burst of damage. This is a proposal generated by the pipeline, not a measured result.
- Some applied drug is proposed to attach reversibly to large molecules in skin, so it can later detach.
- The attached drug is proposed to remain in skin during the treatment break.
- Ingredients in the next application are proposed to compete for attachment sites, shifting retained drug from an attached store into a brief increase in free drug.
- The brief increase in free active drug is proposed to cause additional skin damage.
- Removing the attached store or the competing ingredient is predicted to prevent this extra damage when treatment restarts.
A coat rack can hold the same number of coats before two arrivals, yet leave different numbers on the floor if one arrival knocks the hanging coats off. Counting coats beforehand would miss the difference caused by their release.
Where the picture breaks: Drug attachment is a reversible molecular interaction, not a mechanical collision. The picture does not establish that application ingredients displace drug or that released drug reaches a damaging level.
- Master questionstep 01 of 04
The goal is a therapy that brings the functional condition of middle-aged human skin closer to that of young people.
Rests on: The supplied goal makes youthful skin function the intended outcome, but does not define which functions would be measured.
Stated in the chain - Goal pillarstep 02 of 04
Limiting damage accumulated through repeated repair is selected as a route toward better skin function.
Rests on: The goal requires improved function, but does not identify repeated repair as a cause of its decline.
AssumptionThe chain assumes that repeated repair contributes cumulative damage that matters to the skin functions the therapy aims to restore.
- Gap questionstep 03 of 04
A stronger reaction after a treatment break might persist despite the same drug concentration in tissue. The question is whether removing drug left from earlier treatment prevents irritation from increasing across restarts.
Rests on: The preceding stage names accumulated damage from repeated repair, but supplies no connection to drug retention or treatment breaks.
LeapThe missing connection is why the intended therapy involves repeated drug applications and why retained drug is a candidate cause of the cumulative damage. The supplied chain does not specify the therapy.
- Hypothesisstep 04 of 04
Drug attached to large molecules in skin is proposed to remain through a treatment break. Ingredients in the next application could compete for those attachment sites, releasing the old drug and briefly increasing its free form, meaning drug not attached to those molecules. That increase is proposed to cause additional damage even when the total amount present before restarting is unchanged.
Rests on: The preceding question explicitly identifies drug remaining after a break and equal tissue concentration as the problem to explain. The hypothesis supplies a proposed distinction between total drug and the free drug available after restarting.
Stated in the chain
What is carried, and what is not. Of the five proposed mechanism links, one has direct partial support: S1, an abstract from Molecular Pharmaceutics (2021), reports that skin binding matters to the local distribution of scopolamine, but does not establish reversible storage through a break, displacement, or damage. None of the supplied sources establishes the sequence end to end.S1
Where the reasoning is carried by something unstated · 2
- Goal pillar. The chain assumes that repeated repair contributes cumulative damage that matters to the skin functions the therapy aims to restore.
- Gap question. The missing connection is why the intended therapy involves repeated drug applications and why retained drug is a candidate cause of the cumulative damage. The supplied chain does not specify the therapy. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Irritation after applying a drug-free vehicle, meaning the carrier mixture without the treatment drug, could be attributed to released old drug even if the carrier itself irritates skin or changes its protective barrier. What closes it: The proposed controls for the carrier's own irritation and comparable barrier condition are necessary. Comparisons must also establish whether removing a competing ingredient changes irritation independently of its ability to release retained drug.
- Equal total drug amounts, or similar averages across samples, could be mistaken for equal exposure while a short-lived or localized increase in free drug goes undetected. What closes it: The proposed isotope label, a distinguishable atomic form used to track the earlier dose, must be combined with separate measurements of attached and free drug and sufficiently frequent sampling. The comparison also requires matching drug across tissue locations and time, including active metabolites, meaning drug breakdown products that still have biological effects; a criterion for adequate matching is not supplied.
- Failure to produce irritation after attempting to remove the stored drug could be credited to removal even if the procedure instead changes the tissue's ability to respond. Conversely, continued irritation could reject the hypothesis prematurely if the stored drug was not actually removed. What closes it: Measurements must verify removal of the attached drug. A comparison undergoing the same handling without effective removal is needed, alongside confirmation of comparable barrier condition and the proposed reproduction of the free-drug increase in previously untreated tissue.
What would make this wrong. A persistently stronger response in previously treated skin despite verified matching of free active drug and active breakdown products across tissue locations and time would contradict the hypothesis's central prediction. It would support the need for an additional carrier of treatment history, but would not by itself establish either supplied rival: persistent bacterial-virus activity or retained cholesterol crystals.
What it would change. If the mechanism held, limiting cumulative treatment damage would require controlling drug retained between applications and ingredients capable of releasing it. Matching the total amount of drug in skin would not by itself establish an equally tolerated restart. Even then, a test in isolated tissue would not establish that this approach restores middle-aged human skin to youthful function or remains beneficial over repeated treatment courses; the supplied material defines neither that functional outcome nor the hypothesis's named stabilization measure, SPV_12.
Sources read · 10
Skin Pharmacokinetics of Transdermal Scopolamine: Measurements and Modeling. · Molecular pharmaceutics · 2021
“The scopolamine concentration versus time profiles in SC and VT skin compartments, in vitro and in vivo, taken together with IVRT release and IVPT penetration kinetics, reflect the input rate and drug delivery specifications of the Scopoderm transdermal patch and reveal the importance of skin binding with respect to local drug disposition.”
Does not settle: Абстракт указывает на важность связывания в коже для локального распределения скополамина, но не устанавливает обратимость связывания, вытеснение препарата компонентами следующего нанесения, дополнительный пик свободной активной формы, раздражение или повреждение кожи, а также условия, при которых реакция исчезает или стабилизируется SPV_12.
Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation. · Pharmaceutics · 2023
“Because of the binding of the SLS-loaded gel to the keratin in the subcutaneous (SC), ionic and hydrophobic interactions cause the SC to swell.”
Does not settle: Источник не устанавливает обратимое связывание самого препарата с тканевыми макромолекулами, его высвобождение при следующем нанесении, пики свободной активной формы, роль метаболитов, усиление раздражения при возобновлении терапии или изменение SPV_12.
Topical drug delivery by Sepineo P600 emulgel: Relationship between rheology, physical stability, and formulation performance. · International journal of pharmaceutics · 2024
“the derived skin/vehicle partition coefficient suggested the ionic interaction between lidocaine and Sepineo polymer reducing the free drug, i.e., thermodynamic activity and hence the flux with increasing Sepineo P600 concentration.”
Does not settle: Источник не устанавливает обратимое связывание препарата с тканевыми макромолекулами, вытеснение ранее связанного препарата при следующем нанесении, пик свободной активной формы или повреждение кожи.
Ethosomal Gel for Improving Transdermal Delivery of Thymosin β-4. · International journal of nanomedicine · 2019
“The skin was fixed in Franz diffusion cells”
Does not settle: Источник описывает проницаемость Tβ-4 через изолированную кожу мышей. Он не устанавливает обратимое связывание препарата с тканевыми макромолекулами, конкурирующее вытеснение при следующем нанесении, пик свободной активной формы, раздражение кожи или изменения SPV_12.
Cocrystallization as a novel approach to enhance the transdermal administration of meloxicam. · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2018
“This greater amount of free drug in the solution could contribute to explain the higher transdermal absorption and shorter lag time of this system.”
Does not settle: The source does not establish reversible binding of drug to skin macromolecules, retention during a treatment break, competitive displacement by a subsequent application, a released-drug peak, skin irritation or damage, or the proposed spatial and temporal profile predictions.
Formulation and characterization of antibiotic drug loaded aquasome for the topical application. · Future science OA · 2024
“The formulated cephalothin-loaded aquasomes exhibited stable properties, controlled drug release and significant antibacterial activity against bacteria.”
Does not settle: Источник не исследует обратимое связывание препарата с тканевыми макромолекулами, конкуренцию компонентов последовательных нанесений, высвобождение удержанного препарата, пики свободной активной формы или раздражение кожи.
Development and Characterization of Thiolated Cyclodextrin-Based Nanoparticles for Topical Delivery of Minoxidil. · Pharmaceutics · 2023
“Uptake and drug retention experiments were carried out for 180 min.”
Does not settle: Источник описывает однократный эксперимент по удержанию миноксидила в коже. Он не устанавливает обратимое связывание с тканевыми макромолекулами, конкурирующее вытеснение при следующем нанесении, пик свободного препарата или усиление раздражения.
Physicochemical characterization of the metamorphosis of film-forming formulations of betamethasone-17-valerate. · International journal of pharmaceutics · 2024
“In vitro release tests of either sprayed or pipette-deposited films into either aqueous or ethanolic receptor solutions revealed drug release kinetics dominated by the residual film post-metamorphosis.”
Does not settle: Источник не устанавливает обратимое связывание препарата с тканевыми макромолекулами, конкуренцию компонентов последовательных нанесений, быстрое высвобождение ранее удержанного препарата, пики свободной активной формы или повреждение и раздражение кожи.
Formulation and evaluation of Ocimum basilicum-based emulgel for wound healing using animal model. · Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
“Franz diffusion cell was used for in vitro drug release studies using a dialysis membrane as described in literature ( ).”
Does not settle: The source text does not establish reversible tissue-macromolecule binding, competition-induced displacement of retained drug, a post-application free-drug peak, skin irritation caused by such a peak, or stabilization after removing a bound residue or displacing component.
Inhibitory effect of toluene on tumor promotion in mouse skin. · Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) · 1986
“The toluene inhibition of tumorigenesis was not a direct chemical action on PMA since similar effects occurred whether toluene was the vehicle for PMA or whether it was applied up to 1 day before PMA (i.e., prepromotion).”
Does not settle: Не устанавливает обратимое связывание препарата с тканевыми макромолекулами, конкурентное вытеснение, пики свободной активной формы, повреждение кожи после возобновления нанесения или SPV_12.
The gap this hypothesis explains
Does restarting treatment worsen irritation at equal tissue drug levels, and does clearing leftover drug prevent worsening?
Original wording · exactly as the pipeline generated it
Сохраняется ли усиленная реакция после перерыва при одинаковой тканевой концентрации препарата, и предотвращает ли устранение остаточной экспозиции нарастание раздражения при повторном возобновлении терапии?
What this question is asking
The question concerns whether skin responds more strongly when drug treatment resumes after a break. It asks whether that stronger response remains when the amount of drug in the tissue is the same as during the earlier treatment. It also asks whether removing drug left over from earlier treatment prevents irritation from increasing across repeated restarts, compared with restarting while leftover drug remains. The wording assumes that a stronger response and progressively worsening irritation occur, but the supplied sources do not establish those patterns for the intended setting of improving skin function in middle-aged people.
- Tissue drug concentration
- The amount of a drug within a specified amount of tissue. Matching this measurement is the question's way of asking whether a stronger reaction can occur without a higher measured drug level.
- Residual exposure
- Continued exposure to drug left over from earlier treatment. The question asks whether eliminating this exposure prevents irritation from worsening; the supplied sources do not establish that it occurs in the intended setting.
- Drug clearance
- Removal of drug from the relevant tissue or body. Here, clearance means eliminating leftover drug rather than merely stopping further applications.
- Irritation
- An unwanted local reaction to treatment. The question does not specify which signs or symptoms count, how they are measured, or what would qualify as worsening.
- Inflammation
- A tissue response involving immune activity. S9 measures skin inflammation in mice; this outcome cannot automatically be treated as the same thing as treatment irritation in human skin.
- Contact sensitization
- Development of acquired allergic sensitivity to a substance that contacts the skin. It is a different outcome from irritation, so the absence reported in S1 does not settle the restart question.
- Allergic symptoms
- Symptoms attributed to an immune reaction against a substance. Their return after restarting a drug in S10 does not by itself establish stronger local irritation or increasing severity over successive restarts.
- Absorption
- Movement of an applied drug into tissue or into the wider body. Absorption studies address where drug goes, but do not necessarily establish how tissue reacts when treatment resumes.
- Psoriasis-like mouse model
- An experimental condition in mice intended to resemble aspects of psoriasis, an inflammatory skin disease. Its findings concern that model and do not directly establish the same response in human skin.
- Repeat challenge
- A renewed exposure used to provoke a response. S9 reports a repeat challenge at the same skin site, which is not enough to establish what happens during repeated restarts of the proposed therapy.
- Redistribution
- A change in where cells are located. S9 reports persistence of a redistribution pattern after withdrawal; this is not a measurement of drug remaining in tissue.
- Case report
- A description of an individual clinical case. S10 establishes what was reported in that case, without establishing how commonly the response occurs.
An enhanced response occurs after a treatment break, and irritation increases with repeated treatment restarts.
The assumption is that tissue reacts more strongly after treatment resumes and that irritation builds across successive restarts. Drug remaining in the tissue is treated as a possible contributor to that pattern. Establishing the pattern would provide the effect whose dependence on leftover drug the question asks about.
S9 reports more severe skin inflammation after a repeat challenge at the same site in previously treated mice, supporting a narrower version of a stronger response after withdrawal. S10 reports the return of allergic symptoms after one drug restart, which establishes recurrence in that case rather than progressive irritation. Neither establishes increasing irritation across repeated restarts in middle-aged human skin, and neither tests matched tissue drug levels or removal of residual exposure.S9S10
The same question asked without the part nothing read establishes:
- At the same tissue drug level, is skin irritation greater after restarting treatment than during the earlier treatment period?
- Does removing drug remaining from earlier treatment change skin irritation across repeated treatment restarts?
- Stronger response persists; clearing leftover drug prevents worsening This combination would indicate that the measured tissue drug level alone does not explain the stronger response after a break. It would also support a contribution from leftover drug to worsening across restarts, without establishing that both effects have the same cause.
- Stronger response persists; clearing leftover drug does not prevent worsening The stronger response would remain despite matching tissue drug levels. Removing leftover drug would therefore be insufficient to prevent worsening, and treating clearance as protection against irritation would be unsupported.
- Stronger response disappears; clearing leftover drug prevents worsening The comparison would provide no evidence of a stronger response at equal tissue drug levels. Prevention of worsening after clearance would support a contribution from leftover exposure, although it would not establish the full mechanism.
- Stronger response disappears; clearing leftover drug does not prevent worsening The comparison would provide no evidence of a stronger response at equal tissue drug levels. Failure of clearance to prevent worsening would also leave leftover drug insufficient as an explanation for any increase in irritation across restarts.
Drug remaining in tissue could contribute to exposure when treatment resumes; this is a possibility posed by the question, not a finding established by the supplied sources. If a stronger response persisted at the same tissue drug level, the measured level alone would not explain the difference. If removing leftover drug prevented worsening, that would support a contribution from continued exposure between treatment periods. Confusing these possibilities could lead to an unsupported expectation that a treatment break or drug clearance prevents irritation, while the supplied evidence also does not establish improved skin function.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Проверяемая гипотеза: часть препарата обратимо связывается с тканевыми макромолекулами и сохраняется во время перерыва. Компоненты следующего нанесения конкурируют за места связывания и быстро высвобождают старый препарат. Возникает дополнительный пик свободной активной формы, вызывающий реальное повреждение. Одинаковое суммарное содержание препарата перед возобновлением совместимо с разным последующим пиком. При полном совпадении пространственных и временных профилей свободного препарата и активных метаболитов усиление реакции должно исчезать. Устранение связанного остатка или вытесняющего компонента должно стабилизировать SPV_12, позволяя возобновлять терапию без нарастания нагрузки.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
После первого курса с изотопно меченным препаратом нанесение основы без новой дозы действующего вещества вызывает кратковременное повышение свободной меченой формы и раздражение. Эффект зависит от способности компонентов основы вытеснять препарат в независимом опыте связывания. После удаления связанного остатка всплеск исчезает; его воспроизведение в ранее не обработанной ткани воспроизводит выраженность повреждения. При одинаковых полных профилях свободной активной формы ранее обработанная и контрольная кожа отвечают одинаково. Сохраняющееся различие после такого выравнивания опровергает гипотезу в пользу самостоятельного носителя предыстории.
Would tell it apart from at least one rival. The prediction specifies observable changes, disappearance of an effect, equivalence under matched exposure profiles, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Проверка возможна вне организма с изотопной меткой, раздельным анализом свободной и связанной фракций и частым отбором проб после повторного нанесения основы. Необходимы контроль собственного раздражающего действия основы и подтверждение сопоставимого состояния барьера. Отсутствие доступной метки или метода измерения свободной формы ограничит возможность причинного вывода.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
После первого курса с изотопно меченным препаратом нанесение основы без новой дозы действующего вещества вызывает кратковременное повышение свободной меченой формы и раздражение. Эффект зависит от способности компонентов основы вытеснять препарат в независимом опыте связывания. После удаления связанного остатка всплеск исчезает; его воспроизведение в ранее не обработанной ткани воспроизводит выраженность повреждения. При одинаковых полных профилях свободной активной формы ранее обработанная и контрольная кожа отвечают одинаково. Сохраняющееся различие после такого выравнивания опровергает гипотезу в пользу самостоятельного носителя предыстории.
- What would separate them
Virus replication in skin bacteria may amplify irritation when therapy resumes predicts: В колонизированных моделях кожи усиленный ответ сохраняется после подтверждённого удаления препарата. Очищенная фаговая фракция переносит способность к усиленному ответу в ранее не подвергавшуюся терапии модель с теми же бактериями; эффект воспроизводится при последовательном переносе через новые культуры после разведения исходных растворимых медиаторов ниже действующих концентраций. Избирательное прекращение фаговой репликации устраняет усиление при сохранении бактериальной нагрузки. Удаление кристаллов холестерина эффекта не устраняет. Отсутствие переноса и сохранение реакции после подтверждённого прекращения репликации опровергают гипотезу.
- Rival 02 of 02What would separate them
Retained cholesterol crystal seeds may amplify skin inflammation after repeated damage and repair predicts: В стерильных моделях кожи при повторных одинаковых воздействиях усилению ответа предшествует появление кристаллического холестерина. Устранение подтверждённых кристаллов с восстановлением прежнего общего содержания холестерина в некристаллической форме отменяет усиление. Внесение малой массы кристаллических зародышей возвращает его, тогда как равная масса некристаллического холестерина этого не делает. После удаления всех зародышей время до повторного возникновения эффекта становится случайным и зависит от объёма восприимчивой ткани; при сохранённых зародышах задержка сокращается. Сохранение усиления после устранения кристаллов при неизменной жизнеспособности опровергает гипотезу.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.